PharmaPoint: Major Depressive Disorder Report 2014 - Current and Future Players
M2 - 36 mins ago
Research and Markets (http://www.researchandmarkets.com/research/wdh27g/pharmapoint) has announced the addition of the "PharmaPoint: Major Depressive Disorder - Current and Future Players" report to their offering. The report identifies and analyses the key companies shaping and driving the global Major Depressive Disorder market. The report provides insight into the competitive Major Depressive Disorder landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by Our team of industry experts. Scope - Investigation of current and future market competition for Major Depressive Disorder. - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of Major Depressive Disorder sector through market impact analysis, future market scenario and company analysis Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Market Outlook - Forecast - Drivers and Barriers - Global Issues 4 Current and Future Players - Trends in Corporate Strategy - Company Profiles 5 Appendix Companies Mentioned - Lundbeck - Forest Laboratories (Actavis) - Eli Lilly - Pfizer - Otsuka Pharmaceutical - AstraZeneca - Takeda Pharmaceutical - Alkermes - Euthymics Bioscience - Naurex - e-Therapeutics For more information visit http://www.researchandmarkets.com/research/wd...harmapoint
Viibryd (Major Depressive Disorder) - Forecast and Market Analysis to 2023
M2 - 57 mins ago
Research and Markets (http://www.researchandmarkets.com/research/5mvpkt/viibryd_major) has announced the addition of the "Viibryd (Major Depressive Disorder) - Forecast and Market Analysis to 2023" report to their offering. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023. Viibryd (vilazodone) is an SSRI and a 5HT1A receptor partial agonist indicated for the treatment of patients with MDD. Viibryd was licensed from Merck KGaA and developed by Forest (Actavis). Currently, it is only available in the US market and, in 2013, generated sales of $162.5m (Forest Laboratories, 2014). Scope - Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Viibryd including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Viibryd for the US from 2013 to 2023. - Sales information covered for the US. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Viibryd (Vilazodone) 7 Appendix For more information visit http://www.researchandmarkets.com/research/5m...bryd_major
Actavis' shareholders approves planned acquisition of Forest for about USD25bn in cash and stock
M2 - 1 hr 4 mins ago
Specialist pharmaceutical company Actavis (NYSE:ACT) stated on Tuesday that all proposals related to its planned acquisition of Forest Laboratories (NYSE:FRX) were approved by their respective shareholders at the recent shareholder meetings.
Actavis and Forest Shareholders Approve Proposals Related to Actavis' Planned Acquisition of Forest
Business Wire - Tue Jun 17, 3:17PM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that, at shareholder meetings held today, all proposals related to Actavis' planned acquisition of Forest were approved by both Actavis' and Forest's shareholders.
Valeant Receives FDA's Clearance for Restylane - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 17, 2:05PM CDT
Valeant Pharmaceuticals International, Inc. (VRX) announced that the FDA issued a marketing clearance for its Restylane Silk Injectable Gel with 0.3% Lidocaine.
Global Autism Clinical Trials Review 2014
M2 - Tue Jun 17, 9:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vhfbw6/autism_global) has announced the addition of the "Autism Global Clinical Trials Review, H1, 2014" report to their offering. Autism Global Clinical Trials Review, H1, 2014 provides data on the Autism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Autism. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Autism. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Autism Speaks, Inc. - Seaside Therapeutics, LLC - Forest Laboratories, Inc. - Johnson & Johnson - Otsuka Holdings Co., Ltd. - F. Hoffmann-La Roche Ltd. - Bristol-Myers Squibb Company - Coronado Biosciences, Inc. - ZonMw - Dainippon Sumitomo Pharma Co., Ltd. - National Institute of Mental Health - Massachusetts General Hospital - Tehran University of Medical Sciences - Eunice Kennedy Shriver National Institute of Child Health and Human Development - Hugo W. Moser Research Institute at Kennedy Krieger, Inc. - Stanford University - The University of Hong Kong - University of California, Los Angeles - Mount Sinai Hospital - University of California, San Francisco For more information visit http://www.researchandmarkets.com/research/vh...ism_global
COPD Foundation Releases Groundbreaking COPE Survey Results: Low Patient Awareness About COPD Exacerbations Poses Barrier to Effective Management
Business Wire - Tue Jun 17, 8:37AM CDT
Patients with chronic obstructive pulmonary disease (COPD) may need more education and better dialogue with their physicians to effectively manage the progressive respiratory condition and potentially life-threatening complications known as exacerbations (or flare-ups), according to key findings from the new, two-part national COPE (Chronic Obstructive Pulmonary Experience) Survey initiative released today by the COPD Foundation.
Fetzima (Major Depressive Disorder) - Forecast and Market Analysis to 2023
M2 - Tue Jun 17, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lnvwv5/fetzima_major) has announced the addition of the "Fetzima (Major Depressive Disorder) - Forecast and Market Analysis to 2023" report to their offering. Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023. Fetzima (levomilnacipran) is an SNRI indicated for the treatment of MDD and is only available in the US. It gained FDA approval in July 2013 and was launched in December 2013. The product was developed by Forest (Actavis) following a partnership with Pierre Fabre. According to this agreement, Forest Laboratories is responsible for the clinical development and commercialization of Fetzima in the US and Canada, while Pierre Fabre is responsible for manufacturing and supplying the active pharmaceutical ingredient. Scope - Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Fetzima including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Fetzima for the US from 2013 to 2023. - Sales information covered for the US. Key Topics Covered: 1 Table of Contents 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Fetzima (Levomilnacipran) 7 Appendix For more information visit http://www.researchandmarkets.com/research/ln...zima_major
Idiopathic (Essential) Hypertension - Pipeline Review, H1 2014
M2 - Mon Jun 16, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h6fdl5/idiopathic) has announced the addition of the "Idiopathic (Essential) Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic (Essential) Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic (Essential) Hypertension and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Idiopathic (Essential) Hypertension - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Idiopathic (Essential) Hypertension pipeline depth and focus of Indication therapeutics Companies Mentioned: - Novartis AG - Actelion Ltd - Forest Laboratories, Inc. - Les Laboratoires Servier SAS - Bayer AG - XOMA Corporation - Ahn-Gook Pharmaceutical Co., Ltd. - PhaseBio Pharmaceuticals, Inc. - Lee's Pharmaceutical Holdings Limited - NanoForm Therapeutics Ltd. For more information visit http://www.researchandmarkets.com/research/h6fdl5/idiopathic
Will Forest Labs Retain Namenda Market Share? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 11:00AM CDT
Forest Laboratories, Inc. (FRX) has postponed the final phase of switching to late 2014 and intends to continue marketing Namenda IR till the fall of 2014.
Actavis Announces Receipt of Requisite Consents and Expiration of Consent Solicitations for Forest Laboratories Senior Notes
PR Newswire - Thu Jun 12, 5:16PM CDT
Actavis plc (NYSE: ACT) today announced that Forest Laboratories, Inc. (NYSE: FRX) has received valid consents (the "Requisite Consents"
Forest Laboratories, Inc. Announces Receipt of Requisite Consents and Expiration of Consent Solicitations for Certain of its Senior Notes
Business Wire - Thu Jun 12, 4:00PM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced that it had received valid consents (the "Requisite Consents"
2014 Report on the International Antibacterial Drugs (minoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/ Fluoroquinolones, Macrolides and Phenicols) Market - Forecast to 2019
PR Newswire Europe - Thu Jun 12, 7:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l2jzql/antibacterial [http://www.researchandmarkets.com/research/l2jzql/antibacterial]) has announced the addition of the "Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" [http://www.researchandmarkets.com/research/l2jzql/antibacterial] report to their offering.
Consent Expiry Extensions, Collaborations, Grants, Conference Presentations, and FDA Approvals - Analyst Notes on Forest Laboratories, Intuitive Surgical, Horizon Pharma, Cubist and BDSI
PR Newswire - Thu Jun 12, 5:10AM CDT
Today, Analysts Review released its analysts' notes regarding Forest Laboratories, Inc. (NYSE: FRX), Intuitive Surgical, Inc. (NASDAQ: ISRG), Horizon Pharma Inc (NASDAQ: HZNP), Cubist Pharmaceuticals Inc (NASDAQ: CBST) and BioDelivery Sciences International, Inc. (NASDAQ: BDSI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3640-100free.
Arrhythmias - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3k97mr/arrhythmias) has announced the addition of the "Arrhythmias - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Arrhythmias, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arrhythmias and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Arrhythmias - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Arrhythmias and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Arrhythmias products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Mentioned: - Gilead Sciences - Forest Laboratories - Orion - Compugen - SciFluor For more information visit http://www.researchandmarkets.com/research/3k...rrhythmias
Forest Laboratories plans to continue marketing both NAMENDA TABLETS and once-daily NAMENDA XR up to autumn of 2014
M2 - Wed Jun 11, 7:12AM CDT
Pharmaceutical company Forest Laboratories (NYSE:FRX) said on Tuesday that it will continue to market both its NAMENDA (memantine HCl) 5 mg and 10 mg tablets and once-daily NAMENDA XR (memantine HCl) extended-release capsules through to the the autumn of this year.
Actavis Prices $3.7 Billion of Senior Unsecured Notes
PR Newswire - Tue Jun 10, 4:19PM CDT
Actavis plc (NYSE: ACT) today announced that its indirect subsidiary, Actavis Funding SCS, priced a private debt offering of $500 million of 1.300% senior unsecured notes due 2017, $500 million of 2.450% senior unsecured notes due 2019, $1.2 billion of 3.850% senior unsecured notes due 2024 and $1.5 billion of 4.850% senior unsecured notes due 2044, for a total offering of $3.7 billion in aggregate principal amount. The offering is expected to close on June 19, 2014, subject to market conditions and other factors.
Forest Laboratories Announces Intention to Continue Marketing Both NAMENDA(R) TABLETS and Once-Daily NAMENDA XR(R) Into the Fall of 2014
Business Wire - Tue Jun 10, 3:01PM CDT
-- Initiatives to Ensure Robust and Reliable Product Supply Progressing--
Actavis Announces Offering of Senior Unsecured Notes
PR Newswire - Tue Jun 10, 7:48AM CDT
Actavis plc (NYSE: ACT) today announced that its indirect subsidiary, Actavis Funding SCS, is privately offering three, five, ten and thirty year senior unsecured notes.